Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.
about
The clinical utility of aflibercept for diabetic macular edemaThe role of aflibercept in the management of diabetic macular edemaTherapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathyThe role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Emerging pharmacotherapies for diabetic macular edema.Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathyCurrent treatments for radiation retinopathy.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.Role of IL-6 in angiotensin II-induced retinal vascular inflammation.The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.The pathogenesis of early retinal changes of diabetic retinopathy.Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularizationRandomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema.Environmental enrichment protects the retina from early diabetic damage in adult rats.The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway.Lasting controversy on ranibizumab and bevacizumab.Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.Current and investigational drugs for the treatment of diabetic retinopathy.The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in ratsAnti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.Relationship between RPE and choriocapillaris in age-related macular degenerationA chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhageContributions of inflammatory processes to the development of the early stages of diabetic retinopathy.Effects of diabetes on the eye.Intravitreal bevacizumab: an analysis of the evidence.Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review.The role of Müller glia and microglia in glaucoma.Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edemaIntravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathyNeovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective reviewStem cell therapies in the treatment of diabetic retinopathy and keratopathy.
P2860
Q26783575-327334CA-5C73-493A-8A03-741FD9EF057AQ26798348-D36894D9-0D36-48B0-B394-05561A66EB04Q27021701-07774FCF-DD94-46B9-A172-B311F832788AQ31061150-80F55EE1-2DF7-43F8-8271-B6CA5FD9DF3AQ33304852-0DDAC473-9EDF-46B2-9CC0-0504109FE865Q33335166-839B695B-4AD4-4B8E-9016-81043A92B3F8Q33492339-FA3FCAE2-0570-4F38-85E3-6406D8D76745Q33665180-6937BA68-42BF-4186-BE32-26824EFABBFBQ33740152-CD2A3CD6-2B07-4D4C-AC8D-C83354071163Q33816926-BCB7D2AE-0C79-4E22-B97E-2B3CF285CB0BQ33845139-219F3474-26D8-4DC6-9E40-5A291848F8C8Q33899231-960CDB2B-8EC8-45A6-A868-0E147CE61D03Q33902419-37A07493-04AA-435D-AFB2-9909F8C38FA3Q34081378-4DC58521-CB59-4BB2-AB60-AB038D4D5F53Q34149599-C707F699-6E79-4C8E-A36F-D17E83E1CB6BQ34206305-0925A326-CED0-4DCF-A0EA-5559BD12856FQ34440571-D9BE63AA-65BA-41EF-A549-D0AA75167E7DQ34518374-833659B3-3669-41A3-86C6-2AED4D282174Q34554380-544B1E50-5D92-414B-8DDA-D64006CE77B7Q34803171-C8AF1AA2-4685-4854-B6FA-938AEC3BABAFQ35111433-68ACAF59-B82E-4C16-A41C-BE1C987C9C3BQ35203189-B1A1B45C-269C-42D1-A2F3-2191FBC75EB4Q35586224-86316CF6-0C01-400A-81A2-DBDBADEA169AQ35641933-6501E514-D7E1-42D4-8DE1-8AA1CAD29A8DQ35826493-DE427812-606D-4936-9950-036E8B917AC5Q36066049-F3718E06-2B29-4D2B-9F6F-ADA2963CC08FQ36425846-A9567993-3952-4B92-B23D-9B8EC721C0B9Q36673663-C18E1A5F-7348-47A0-BA5E-A89466D381D8Q36791715-026FE4D8-CED6-4603-9883-B059AA1571B7Q36796695-BCF01325-61D8-48DE-A618-688D367A0436Q37084522-75CEDBF1-FD4B-44C8-B604-83F985BEF666Q37395307-66D46C10-3512-432F-B133-91BF58A620ABQ37577410-77EFF8D9-0301-49CB-B1AB-6D7A1B34EF04Q37943001-CFB7895D-F163-42E6-B650-3ADFB2B5292EQ38069584-88CF0BE6-38CC-4194-9DEE-B746BD446B74Q38115460-A5A104FF-EDC3-403E-B0D2-84C847360C5AQ38174892-47CAA598-3A6D-4B77-89BD-908710BE0874Q38193826-108356F9-0B21-4D1B-BEB3-723FD308956FQ38364703-680AA829-62C8-4093-AE99-E5DFAC6CCC21Q38603660-0AE0E164-8881-465E-86DA-83FCD60C5162
P2860
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Pathologic features of vascula ...... pathy in the nonhuman primate.
@en
Pathologic features of vascula ...... pathy in the nonhuman primate.
@nl
type
label
Pathologic features of vascula ...... pathy in the nonhuman primate.
@en
Pathologic features of vascula ...... pathy in the nonhuman primate.
@nl
prefLabel
Pathologic features of vascula ...... pathy in the nonhuman primate.
@en
Pathologic features of vascula ...... pathy in the nonhuman primate.
@nl
P2093
P1476
Pathologic features of vascula ...... pathy in the nonhuman primate.
@en
P2093
Anthony P Adamis
D Scott McLeod
Gerard A Lutty
Makoto Taomoto
Michael J Tolentino
Tsuyoshi Otsuji
P304
P356
10.1016/S0002-9394(01)01381-2
P407
P577
2002-03-01T00:00:00Z